XML 26 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (4,054,774) $ (4,681,231)
Stock-based compensation expense included in -    
General and administrative costs 669,146 1,160,649
Research and development costs
Increase (decrease) in -    
Advances on research and development contract services 69,002 3,224
Prepaid insurance 25,994 22,375
Other prepaid expenses and current assets (17,460) (13,708)
Accounts payable and accrued expenses (8,593) 81,433
Research and development contract liabilities (74,457) 23,969
Net cash used in operating activities (3,391,142) (3,403,289)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 3,137,039 5,141,384
Exercise of pre-funded common stock warrants 41
Exercise of common stock options 6,281
Net cash provided by financing activities 3,143,361 5,141,384
Cash:    
Net increase (decrease) (247,781) 1,738,095
Balance at beginning of period 5,353,392 4,823,745
Balance at end of period 5,105,611 6,561,840
Supplemental disclosures of cash flow information:    
Interest 6,088 5,240
Income taxes